Abstract: An improved particle beam inspection apparatus, and more particularly, a particle beam inspection apparatus including an improved load lock unit is disclosed. An improved load lock system may comprise a plurality of supporting structures configured to support a wafer and a conditioning plate including a heat transfer element configured to adjust a temperature of the wafer. The load lock system may further comprise a gas vent configured to provide a gas between the conditioning plate and the wafer and a controller configured to assist with the control of the heat transfer element.

Abstract: This disclosure pertains to the preparation of bifunctional compounds (e.g., Compound 1), intermediates in the preparation of such compounds, and preparation of such intermediates.

Abstract: The present disclosure relates to ultra-pure forms, polymorphs, amorphous forms, and formulations of N-[(1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl]-6-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazin-1-yl}methyl)piperidin-1-yl]pyridazine-3-carboxamide, referred to herein as Compound A: The present disclosure also relates methods of manufacturing and purifying the same, as well as intermediates useful in the synthesis of Compound A. The ultra-pure forms, polymorphs, amorphous forms, and formulations of Compound A can be used as therapeutic agents for the treatment of various diseases and conditions such as cancer.

Abstract: A novel solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N?-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride (also referred to “ATR-101”) suitable for oral dosing, and to compositions, methods and kits relating thereto. ATR-101 has particular utility in the treatment of, for example, aberrant adrenocortical cellular activity, including adrenocortical carcinoma (ACC), congenital adrenal hyperplasia (CAH) and Cushing's syndrome.

Abstract: The present disclosure relates to polymorphic forms of (S)-3-(5-(4-((1-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione, methods of making these polymorphic forms, and compositions comprising these polymorphic forms. These polymorphic forms are useful in the treatment of various diseases, including, for example, breast cancer.

Abstract: A method for providing tests and measurements using a transceiver is disclosed. In some examples, the method may involve using, at least one test instrument and at least one transceiver, to perform tests and measurements at a testing point in a network. The tests and measurements may include at least one of: (1) channel or wavelength and data measurements; (2) insertion loss and optical power measurements; or (3) bit error rate (BER) measurements.

Abstract: A novel solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N?-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride (also referred to “ATR-101”) suitable for oral dosing, and to compositions, methods and kits relating thereto. ATR-101 has particular utility in the treatment of, for example, aberrant adrenocortical cellular activity, including adrenocortical carcinoma (ACC), congenital adrenal hyperplasia (CAH) and Cushing's syndrome.

Abstract: Systems and methods for providing peak current mode control (PCMC) for power converters using discrete analog components. A pair of complementary bipolar junction transistors may be used to set a maximum duty cycle for the power converter. PCMC may be achieved using a comparator that compares peak input current to an error feedback signal and terminates a pulse-width modulation (PWM) pulse when the peak input current exceeds the error feedback signal. A magnetic signal transformer may be used to establish a secondary side bias voltage supply, to return the error signal, and to drive an AC-coupled signal for a synchronous gate drive. A synchronous switch may be turned on when the main switch is turned off via an output winding of the flyback transformer and may be turned off by the trailing edge of a clock pulse from the magnetic signal transformer before the main switch is turned on.

Abstract: A novel solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N?-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride (also referred to “ATR-101”) suitable for oral dosing, and to compositions, methods and kits relating thereto. ATR-101 has particular utility in the treatment of, for example, aberrant adrenocortical cellular activity, including adrenocortical carcinoma (ACC), congenital adrenal hyperplasia (CAH) and Cushing's syndrome.

Abstract: A novel solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N?-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride (also referred to “ATR-101”) suitable for oral dosing, and to compositions, methods and kits relating thereto. ATR-101 has particular utility in the treatment of, for example, aberrant adrenocortical cellular activity, including adrenocortical carcinoma (ACC), congenital adrenal hyperplasia (CAH) and Cushing's syndrome.

Abstract: A novel solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N?-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride (also referred to “ATR-101”) suitable for oral dosing, and to compositions, methods and kits relating thereto. ATR-101 has particular utility in the treatment of, for example, aberrant adrenocortical cellular activity, including adrenocortical carcinoma (ACC), congenital adrenal hyperplasia (CAH) and Cushing's syndrome.

Abstract: A novel solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N?-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride (also referred to “ATR-101”) suitable for oral dosing, and to compositions, methods and kits relating thereto. ATR-101 has particular utility in the treatment of, for example, aberrant adrenocortical cellular activity, including adrenocortical carcinoma (ACC), congenital adrenal hyperplasia (CAH) and Cushing's syndrome.

Abstract: Systems and methods for providing a self-driven synchronous rectification circuit for an active-clamp forward converter which includes automatically enhancing synchronous MOSFETs and maximizing input voltage range. The gate signals for the synchronous MOSFETs are derived from a unipolar magnetic coupling signal instead of a bipolarized magnetic coupling signal. The unipolar signal is retained for fully enhanced driving of the MOSFETs at low line voltage and the unipolar signal is automatically converted to a bipolar signal at high line amplitude due to line variance to maximize input voltage range by utilizing non-polarized characteristics of the MOSFET gate-to-source voltage (Vgs). The circuit permits efficient scaling for higher output voltages such as 12 volts DC or 15 volts DC, without requiring extra windings on the transformer of the forward converter.

Abstract: The present invention is a system and method for automated position location using RF signposting. The present invention comprises a plurality of transmitting units placed throughout a service area. Each transmitting unit repeatedly transmits a signal including position information related to a position associated with the transmitting unit. The position information may be an absolute position or an encoded position based on the structure of a building in which the transmitting unit is located. A receiving unit receives the signal transmitted from a transmitting unit and determines the position of the receiving unit, based on the received indication. The transmitting units are placed to provide uniform coverage of the service area, thus providing position location indoors and in urban areas where GPS does not function properly.

Abstract: A direct signaling system for providing system subscribers with the freedom to access service providers of their choice, regardless of their access network arrangement, with substantially minimum change to existing telecommunication software and architecture. The system provides a home interface unit and a call server that enables a subscriber to send signaling messages to and receive messages from the service providers of their choice. The home interface unit and call server execute state machines that provide specific details of system operation. The call server state machine triggers a state machine and thus operation of the service specific servers chosen by the subscriber.

Abstract: Methods and systems for controlling data transfer operations during a communication session between a transmitter and at least one receiver provide that data packets which have been stored at the receiver memory before a disconnect occurred remain stored in therein in the presence of the disconnect to avoid the need for retransmitting data packets upon re-establishment of a communication link. Data representative of those data packets already stored at the receiver memory is maintained for purposes of synchronizing data packet transmission from the transmitter for completing data file transfer. Data control instructions for implementing storage of data packets and tracking the progression of data packet transmissions when a disconnect occurs may suitably included in an existing protocol layer of a communication system or as an additional protocol layer added to the operating system of the communication system.